Therapeutic oligonucleotide development requires precise control over molecular architecture, backbone chemistry, stereochemistry, and conjugation strategy. Bio-Synthesis supports pharmaceutical and biotechnology programs with advanced oligonucleotide platforms built for structural precision, reproducibility, and scalable manufacturing.
Our capabilities extend beyond standard oligo synthesis to include large-scale production, stereodefined phosphorothioate control (Rp/Sp), and integration of diverse backbone chemistries including PS, PS2, PN, and PACE-type systems. We routinely support non-canonical and complex architectures such as asymmetric duplexes, mixed backbone designs, extended constructs, and conjugation-enabled therapeutic oligos.
siRNA
ASO
Aptamers
SSO
miRNA Mimics
Bioconjugation
Bench to Preclinical
This overview page highlights the major therapeutic oligonucleotide modalities we support, including siRNA synthesis, antisense oligonucleotide (ASO) services, aptamers, splice-switching oligonucleotides (SSO), miRNA mimics, and therapeutic oligo bioconjugation for delivery and targeting.
Therapeutic oligonucleotide platform
Build • Control • Scale
Advanced therapeutic oligonucleotide design with full control over architecture, chemistry, stereochemistry, and conjugation — executed with reproducibility across development and manufacturing scale.
Scale
1000 g+
Large-scale program support
Stereochemistry
Rp / Sp
Stereodefined PS capable
Backbone
PS • PN • PACE
Advanced linkage systems
Design
Flexible
Non-canonical & complex architectures